Special Article
A Randomized, Controlled Trial of Financial Incentives for Smoking Cessation
N Engl J Med 2009; 360:699-709February 12, 2009DOI: 10.1056/NEJMsa0806819
- Abstract
Background
Smoking is the leading preventable cause of premature death in the United States. Previous studies of financial incentives for smoking cessation in work settings have not shown that such incentives have significant effects on cessation rates, but these studies have had limited power, and the incentives used may have been insufficient.
Methods
We randomly assigned 878 employees of a multinational company based in the United States to receive information about smoking-cessation programs (442 employees) or to receive information about programs plus financial incentives (436 employees). The financial incentives were $100 for completion of a smoking-cessation program, $250 for cessation of smoking within 6 months after study enrollment, as confirmed by a biochemical test, and $400 for abstinence for an additional 6 months after the initial cessation, as confirmed by a biochemical test. Individual participants were stratified according to work site, heavy or nonheavy smoking, and income. The primary end point was smoking cessation 9 or 12 months after enrollment, depending on whether initial cessation was reported at 3 or 6 months. Secondary end points were smoking cessation within the first 6 months after enrollment and rates of participation in and completion of smoking-cessation programs.
Results
The incentive group had significantly higher rates of smoking cessation than did the information-only group 9 or 12 months after enrollment (14.7% vs. 5.0%, P<0.001) and 15 or 18 months after enrollment (9.4% vs. 3.6%, P<0.001). Incentive-group participants also had significantly higher rates of enrollment in a smoking-cessation program (15.4% vs. 5.4%, P<0.001), completion of a smoking-cessation program (10.8% vs. 2.5%, P<0.001), and smoking cessation within the first 6 months after enrollment (20.9% vs. 11.8%, P<0.001).
Conclusions
In this study of employees of one large company, financial incentives for smoking cessation significantly increased the rates of smoking cessation. (ClinicalTrials.gov number, NCT00128375.)
Media in This Article
Figure 1
Assessment for Eligibility, Randomization, and Follow-up.Figure 2
Rates of Smoking Cessation in Various Subgroups at 9 or 12 Months.Article Activity
- Article
Smoking remains the leading preventable cause of premature death in the United States, accounting for approximately 438,000 deaths each year.1 Seventy percent of smokers report that they want to quit,2 but annually only 2 to 3% of smokers succeed. 3,4 Although smoking-cessation programs and pharmacologic therapies have been associated with higher rates of cessation, rates of participation in such programs and use of such therapies are low.5,6
Work sites offer a promising venue for encouraging smoking cessation because employers are likely to bear many of the excess health care costs and productivity losses that are due to missed work among smokers. In addition, existing channels of communication can be used to reach smokers and reinforce healthful behavior choices. Previous studies have shown that providing smokers with financial incentives to stop smoking increases enrollment in smoking-cessation programs and short-term cessation rates,7-10 but the studies have not shown significant increases in long-term cessation rates. Similarly, studies of financial-incentive programs in work settings have not shown significant differences in long-term cessation rates,11 though the studies generally were limited by small sample sizes and weak financial incentives.
In this randomized, controlled trial involving employees at a large, multinational company based in the United States, we tested the effectiveness of a financial incentive of up to $750 in improving long-term rates of smoking cessation.
Methods
Study Population
We recruited study participants from February 2005 through November 2006 among employees at company work sites throughout the United States. Potential participants were identified with the use of a survey that asked employees about their smoking habits, their use of other tobacco products, and their willingness to be contacted by researchers from the University of Pennsylvania about participation in a smoking-cessation study. These surveys were distributed through the firm's intranet and, at sites with high proportions of employees who did not have intranet access, through on-site recruiting. Employees were eligible to participate if they were at least 18 years of age and if they reported that they were currently smoking five or more cigarettes per day. Employees were not included in the study if they were currently using tobacco products other than cigarettes or if they planned to leave the firm within 18 months. All participants were followed for at least 12 months; only those with a confirmed negative result within the first 12 months on a cotinine test, a test that is used for biochemical verification of self-reported abstinence, were followed for an additional 6 months.
Study Protocol
The protocol was approved by the institutional review board at the University of Pennsylvania, and all participants provided written informed consent before randomization. All study participants received information about community-based smoking-cessation resources within 20 miles of their work site, as well as the standard health benefits provided by the firm, such as coverage of physician visits and bupropion or other drugs prescribed to promote cessation of tobacco use. Participants in the incentive group were also informed that they would receive financial incentives for completion of a community-based smoking-cessation program ($100); for smoking cessation, confirmed with the use of a cotinine test, within 6 months after study enrollment ($250); and for continued abstinence for an additional 6 months after the initial cessation ($400).
All participants were contacted 3 months after enrollment and asked whether they had stopped smoking. Participants who reported complete abstinence (not even a puff of a cigarette) for at least 7 days before being contacted were interviewed so that we could obtain a more extensive assessment of smoking behavior. Participants who did not report complete abstinence were recontacted 3 months later (i.e., 6 months after enrollment) for the full follow-up assessment. Six months after completing their first full interview (i.e., at 9 months for those who reported quitting at 3 months; at 12 months for those who were interviewed at 6 months), everyone was interviewed again. Participants who reported during any follow-up interview that they had stopped smoking were asked to provide a saliva or urine sample for confirmation of smoking cessation with the use of a cotinine test. Participants with negative results of cotinine tests at both the interview conducted at 3 or 6 months and the interview conducted at 9 or 12 months were also interviewed 12 months after completion of their initial full interview (i.e., at 15 or 18 months).
Participants received $20 per interview for participating in telephone interviews at baseline, at 3 or 6 months, at 9 or 12 months, and at 15 or 18 months. After each interview, participants who reported that they had stopped smoking received $25 for submitting a sample for biochemical verification of the cotinine level.
Randomization Procedures
Participants were randomly assigned to a study group after they provided informed consent. Randomization was performed in permuted blocks of four and was stratified according to work site, income (<200%, 200 to 500%, or >500% of the federal poverty level, which was $9,800 for a single person and $20,000 for a family of four in 2006), and heavy or nonheavy smoking (with heavy smoking defined as two or more packs of cigarettes per day). The randomized assignments were concealed until all eligibility criteria had been entered in an electronic tracking system; however, blinding could not be maintained after this point because of the nature of the intervention.
Assessments of End Points
The primary end point was the participant's self-report of abstinence at both 3 and 9 months or at both 6 and 12 months after study enrollment. Abstinence was biochemically confirmed by a negative result of a cotinine test performed on a saliva or urine sample. Self-reported continuous abstinence from all tobacco products was defined as abstinence for a minimum of 7 days before the 3- or 6-month interview (point prevalence) and abstinence for the duration of the period from the 3- or 6-month interview to the 9- or 12-month interview (prevalence of prolonged abstinence).
Secondary end points included enrollment in a smoking-cessation program; completion of a smoking-cessation program; rates of smoking cessation within 6 months after study enrollment; and rates of smoking cessation at 3, 9, and 15 months or 6, 12, and 18 months after study enrollment. Participants were classified as having completed the smoking-cessation program if they provided a certificate of completion from the sponsoring organization.
All follow-up assessments were conducted with the use of a telephone interview. Self-reported cessation was verified by saliva cotinine tests (with a cotinine level of <15 ng per milliliter considered to be an indication of smoking cessation)12 or by urine cotinine tests (with a level of <2 ng per milliliter considered to be an indication of smoking cessation).13 Urine cotinine tests were used only in the case of participants who were using nicotine-replacement therapy, in whom testing of anabasine and anatabine levels in the urine was performed. Participants who reported abstinence but who had saliva or urine cotinine levels above the cutoff points were classified as smokers. Participants who were lost to follow-up were classified as relapsed smokers.
The collection of samples was coordinated by the study staff in conjunction with the health-promotion staff at the firm and, at small work sites that did not have onsite health facilities, through contract with Examination Management Services (Scottsdale, AZ). Participants' identities were confirmed and samples were analyzed at the Clinical Pharmacology Laboratory at the University of California, San Francisco.
Baseline Variables
The pretreatment level of nicotine dependence was assessed according to the number of cigarettes smoked per day, the number of years of smoking, and the score on the Fagerström Test for Nicotine Dependence14 (which has a range of 0 to 10, with higher scores indicating more nicotine dependence); participants with a score of 6 or greater were classified as highly dependent on nicotine.15 We also collected information on income, work site, baseline health status, and interest in quitting, as measured by baseline readiness to stop smoking (i.e., the “stage of change,” as defined by DiClemente et al.16 and Prochaska et al.17).
Statistical Analysis
The primary analysis was an unadjusted intention-to-treat analysis of the difference in biochemically confirmed cessation rates between the incentive and control groups at both 3 and 9 months or at both 6 and 12 months. The analysis was performed with the use of Pearson's chi-square test, or with the use of Fisher's exact test, if there were five or fewer participants per cell. We used a similar approach to estimate differences in rates of cessation within 6 months after enrollment; rates of enrollment in and completion of smoking-cessation programs; and cessation rates at 3, 9, and 15 months or 6, 12, and 18 months after study enrollment. Unadjusted odds ratios for cessation were estimated and were compared with odds ratios that were adjusted for the stratification variables (work site, degree of nicotine dependence, and income) as well as the set of baseline covariates shown in Table 1Table 1
Characteristics of the Study Participants.; variable-selection methods were not applied. The similarity of the study groups with respect to covariates at baseline was analyzed by the chi-square test for categorical variables and the Student's t-test or Wilcoxon rank-sum test for continuous variables, as appropriate.Although subgroup analyses were not prespecified, we looked at cessation rates in subgroups that were defined by seven baseline variables: sex, income (<200%, 200 to 500%, and >500% of the federal poverty level), heavy smoking (≥2 packs per day) or nonheavy smoking, number of previous attempts to quit (0 to 2, 3 or 4, or ≥5), stage of quitting as defined by Prochaska et al.17 (precontemplation, contemplation, or preparation), self-assessed health (poor, fair, good, very good, or excellent), and nicotine dependence as assessed by the score on the Fagerström Test for Nicotine Dependence (<6 or ≥6). The homogeneity of the association (i.e., interaction) between the group assignment and cessation rates across subgroups was assessed with the use of the Cochran–Mantel–Haenszel test. Within each subgroup, rates of cessation in the incentive and control groups were compared with the use of chi-square tests.
Our power calculations were based on expected 12-month cessation rates of 3.0% in the control group and 9.4% in the incentive group. To have 80% power to show a difference between groups, with a 1% two-sided type I error, we needed to have 360 participants in each group; we increased that number by 15%, to 425 in each group, to account for loss to follow-up resulting from expected employee turnover. No interim analyses were planned or conducted. All reported P values are two-sided and were not adjusted for multiple comparisons.
Results
Figure 1Figure 1
Assessment for Eligibility, Randomization, and Follow-up. shows the numbers of subjects who were screened and who participated in the study intervention and follow-up. Of the 1903 people who initially expressed interest in participating, 878 (46%) were enrolled; 436 participants were randomly assigned to the incentive group, and 442 to the control group. Demographic characteristics, smoking behavior, degree of nicotine dependence, readiness to quit, and health status were similar in the incentive and control groups (Table 1). Participants in both groups smoked approximately one pack of cigarettes per day, and approximately 5 to 6% of the participants were heavy smokers. The majority of the sample had incomes that were greater than 500% of the poverty level, and approximately 90% of the participants were white. A similar number of participants in the incentive and control groups were lost to follow-up or withdrew in the first 6 months (66 and 59 participants, respectively; P=0.45) and through month 12 (56 and 47, respectively; P=0.25).The 9-month or 12-month rate of cessation, as confirmed by cotinine testing, was 14.7% in the incentive group, as compared with 5.0% in the control group (P<0.001) (Table 2Table 2
Smoking-Cessation End Points According to Group Assignment.). In both the incentive group and the control group, very few of the participants who reported that they had quit smoking did not submit samples for testing (0.5% and 1.1%, respectively), and no participants who submitted samples had positive test results. The rate of participation in a smoking-cessation program was significantly higher in the incentive group than in the control group (15.4% vs. 5.4%, P<0.001), and a significantly higher percentage of incentive-group participants completed a smoking-cessation program (10.8% vs. 2.5%, P<0.001). Members of the incentive group who participated in a smoking-cessation program had significantly higher rates of cessation than did members of the control group who participated in such a program (46.3% vs. 20.8%, P=0.03).The cotinine-confirmed cessation rate within 6 months after study enrollment was 20.9% in the incentive group, as compared with 11.8% in the control group (P<0.001). The cessation rate at 15 or 18 months was 9.4% in the incentive group, as compared with 3.6% in the control group (P=0.001). Among participants who had not stopped smoking in the first 6 months — and thus were ineligible for financial incentives — the cotinine-confirmed cessation rates were similar in the incentive and control groups (4.1% and 5.9%, respectively; P=0.29).
The odds ratios for quitting by 9 or 12 months (Table 3Table 3
Odds Ratios for Long-Term (9- or 12-Month) Smoking Cessation.) were significantly higher in the incentive group than in the control group in the unadjusted model (odds ratio, 3.28; 95% confidence interval [CI], 1.98 to 5.44), in a logistic-regression model that adjusted for stratification variables only (odds ratio, 3.19; 95% CI, 1.91 to 5.30), and in a model that adjusted for all the variables included in Table 1 (odds ratio, 3.16; 95% CI, 1.88 to 5.32). Exploratory Subgroup Analyses
Figure 2Figure 2
Rates of Smoking Cessation in Various Subgroups at 9 or 12 Months. shows 9-month or 12-month cessation rates stratified according to subgroup. For all subgroups, members of the incentive group had higher cessation rates than members of the control group. None of the tests for interaction showed significant differences in this population; instead, the observed patterns showed a consistent effect of the intervention across numerous characteristics.Discussion
In this study of employees at a large corporation, rates of prolonged abstinence from smoking after 9 or 12 months of follow-up were 14.7% in the group that was eligible for financial incentives and 5.0% in the control group. Rates of prolonged abstinence at 15 or 18 months in the incentive group remained significantly higher than those in the control group.
A 2005 Cochrane Collaboration review of financial incentives for smoking cessation in workplace settings concluded that there was insufficient evidence that these incentives are effective.11 One reason for this finding may be that many previous studies were not designed with samples that were large enough to detect the differences we observed. A second reason may be that the incentives used in previous studies have generally been small (as little as $10 in some of them). Studies have shown that financial-incentive programs are associated with an increased rate of smoking cessation in the short term, but the programs reported in these studies were not designed to focus on sustaining high rates over time.7,9 The relationships of the size and structure of incentive payments to rates of smoking cessation remain important empirical questions that need to be addressed in future research. It is possible that larger — or smaller — payments by employers could be more cost-effective in improving smoking-cessation rates. The optimal design of incentive programs for smoking cessation is also an open question, since extension of the incentives beyond 12 months may result in higher cessation rates over a longer period.
The cotinine level, which we used for biochemical verification of 7-day abstinence, is considered to be the best biomarker of smoking cessation.12 Consistent with the recommendations of the Society for Research on Nicotine and Tobacco, our primary measure of self-reported cessation at both 9 or 12 months and 15 or 18 months was prolonged abstinence.12 Although prolonged abstinence can be biochemically verified only indirectly because of the limitations of the cotinine test, it is likely that the point prevalence is highly correlated with prolonged abstinence 6 months after short-term quitting was assessed.12
To date, financial incentives within health care settings have been directed primarily toward providers, through Pay for Performance (P4P) programs. However, given that up to 40% of premature deaths in the United States are due to unhealthful behaviors such as smoking, poor dietary habits, and sedentary lifestyles,18 incentives directed toward patients rather than providers may have greater potential for changing health behaviors.19-21 One approach to encouraging smoking cessation would be to adjust health-insurance premiums on the basis of smoking status; however, targeted payments for smoking cessation have the advantage of being unbundled from health-insurance premiums and thus may be more salient to people, thereby having a greater influence on behavior.22
The financial benefit to employers of having their employees stop smoking is estimated to be about $3,400 per year23 as a result of increased productivity, decreased absenteeism, and a reduced incidence of illness. There is also strong evidence that employees prefer to work for firms that offer effective and attractive benefit programs.24 However, few employers offer full coverage of smoking-cessation services or cessation programs in the workplace,8,25,26 partly because a compelling “business case” for such coverage has not been made. Notably, neither the financial-incentive intervention nor the control intervention in our study included the establishment of a smoking-cessation program; both interventions merely encouraged participants to use existing programs.
The literature on smoking cessation suggests that most relapses occur within the first month of cessation, that approximately 90% of relapses occur within the first 6 months,27 and that the likelihood of continuous abstinence over a 20-month period is about 95% for smokers who quit for 1 year or longer.12 Our finding of relapse rates between the 9- or 12-month visit and the 15- or 18-month visit (27.3% in the control group and 35.9% in the incentive group) that appear to be higher than those reported in the literature may suggest that relapse rates differ according to whether smoking cessation occurs in the presence or absence of incentives. However, since the relapse rates in both the incentive and control groups differ from those in the literature, and in view of the relatively small number of participants in our study who quit smoking, we cannot be confident that the relapse rates do in fact differ from those previously reported.
Because approximately 90% of the enrolled population was white and the participants had relatively high education and income levels, our study may have limited generalizability to employees with lower socioeconomic status than that of the participants in our study or to members of a minority racial or ethnic group. In addition, programs that are designed to change behavior may have unintended consequences that we could not observe in our study. However, we think it is unlikely that substantial numbers of people would start smoking in order to be eligible for such incentive programs. Studies such as this one are subject to selection bias, in that smokers who voluntarily enroll in these programs may be more likely (whether they are assigned to the incentive group or the control group) to quit smoking; it is difficult to project how effective these programs would be in a population that included all employees within a given company.
In summary, this study shows that smoking-cessation rates among company employees who were given both information about cessation programs and financial incentives to quit smoking were significantly higher than the rates among employees who were given program information but no financial incentives.
Supported by grants from the Centers for Disease Control and Prevention (RO1 DP000100-01 and RO1 DP001168-01) and from the Pennsylvania Department of Health, which specifically disclaims responsibility for any analyses, interpretations, or conclusions.
Dr. Volpp reports receiving lecture fees from Aetna and grant support from Aetna and Pfizer and owning equity in General Electric; Dr. Pauly, being a board member of Independent Health, owning equity in General Electric, receiving lecture fees from America's Health Insurance Plans, and receiving grant support from Merck and MedStar; Dr. Glick, owning equity in General Electric; and Dr. Galvin, owning equity in General Electric. No other potential conflict of interest relevant to this article was reported.
We thank Quincy Greene for his contributions to the analyses for this article and Donna Tomlinson, M.D., for assistance in implementing this study.
Source Information
From the Center for Health Equity Research and Promotion, Philadelphia Veterans Affairs Medical Center (K.G.V., D.A.A.); the Center for Health Incentives, Leonard Davis Institute of Health Economics (K.G.V., A.B.T., M.V.P., H.A.G., D.A.A., J.Z., J.D., J.W.), the Department of Health Care Management, the Wharton School (K.G.V., M.V.P., H.A.G., A.P., D.A.A.), and the Center for Clinical Epidemiology and Biostatistics and Department of Biostatistics and Epidemiology (A.B.T., F.W.), University of Pennsylvania; the Department of Medicine (K.G.V., H.A.G., D.A.A., J.Z., J.D., E.C.) and the Transdisciplinary Tobacco Use Research Center, Department of Psychiatry (J.A.-M.), University of Pennsylvania School of Medicine — all in Philadelphia; General Electric, Fairfield, CT (R.G.); and Yale University School of Medicine, New Haven, CT (R.G.).
Address reprint requests to Dr. Volpp at the Division of General Internal Medicine and Department of Health Care Management, University of Pennsylvania School of Medicine and the Wharton School, 1232 Blockley Hall, 423 Guardian Dr., Philadelphia, PA 19104-6021, or at volpp70@wharton.upenn.edu.
- References
References
1
Mokdad AH ,Marks JS ,Stroup DF ,Gerberding JL . Actual causes of death in the United States, 2000. JAMA 2004;291:1238-1245[Erratum, JAMA 2005;293:293-4, 298.]
CrossRef | Web of Science | Medline2
Cigarette smoking among adults -- United States, 2000. MMWR Morb Mortal Wkly Rep 2002;51:642-645
Medline3
Annual smoking-attributable mortality, years of potential life lost, and productivity losses -- United States, 1997-2001. MMWR Morb Mortal Wkly Rep 2005;54:625-628
Medline4
Tobacco use among adults -- United States, 2005. MMWR Morb Mortal Wkly Rep 2006;55:1145-1148
Medline5
Zhu S ,Melcer T ,Sun J ,Rosbrook B ,Pierce JP . Smoking cessation with and without assistance: a population-based analysis. Am J Prev Med 2000;18:305-311
CrossRef | Web of Science | Medline6
Fiore MC . US Public Health Service Clinical Practice Guideline: treating tobacco use and dependence. Respir Care 2000;45:1200-1262
Medline7
Volpp KG ,Gurmankin Levy A ,Asch DA , et al. A randomized controlled trial of financial incentives for smoking cessation. Cancer Epidemiol Biomarkers Prev 2006;15:12-18
CrossRef | Web of Science | Medline8
Hennrikus DJ ,Jeffery RW ,Lando HA , et al. The SUCCESS project: the effect of program format and incentives on participation and cessation in worksite smoking cessation programs. Am J Public Health 2002;92:274-279
CrossRef | Web of Science | Medline9
Donatelle RJ ,Prows SL ,Champeau D ,Hudson D . Randomised controlled trial using social support and financial incentives for high risk pregnant smokers: Significant Other Supporter (SOS) program. Tob Control 2000;9:Suppl 3:III67-III69
CrossRef | Medline10
Donatelle RJ ,Hudson D ,Dobie S ,Goodall A ,Hunsberger M ,Oswald K . Incentives in smoking cessation: status of the field and implications for research and practice with pregnant smokers. Nicotine Tob Res 2004;6:Suppl 2:S163-S179
CrossRef | Web of Science | Medline11
Hey K ,Perera R . Competitions and incentives for smoking cessation. Cochrane Database Syst Rev 2005;2:CD004307-CD004307
Medline12
SRNT Subcommittee on Biochemical Verification
CrossRef | Medline13
Jacob P III ,Hatsukami D ,Severson H ,Hall S ,Yu L ,Benowitz N . Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev 2002;11:1668-1673
Web of Science | Medline14
Heatherton TF ,Kozlowski LT ,Frecker RC ,Fagerstrom KO . The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991;86:1119-1127
CrossRef | Medline15
Westman EC ,Behm FM ,Simel DL ,Rose JE . Smoking behavior on the first day of a quit attempt predicts long-term abstinence. Arch Intern Med 1997;157:335-340
CrossRef | Web of Science | Medline16
DiClemente CC ,Prochaska JO ,Fairhurst SK ,Velicer WF ,Velasquez MM ,Rossi JS . The process of smoking cessation: an analysis of precontemplation, contemplation, and preparation stages of change. J Consult Clin Psychol 1991;59:295-304
CrossRef | Web of Science | Medline17
Prochaska JO ,DiClemente CC ,Velicer WF ,Rossi JS . Standardized, individualized, interactive, and personalized self-help programs for smoking cessation. Health Psychol 1993;12:399-405
CrossRef | Web of Science | Medline18
Schroeder SA . Shattuck Lecture: We can do better -- improving the health of the American people. N Engl J Med 2007;357:1221-1228
Free Full Text | Web of Science | Medline19
Sindelar JL . Paying for performance: the power of incentives over habits. Health Econ 2008;17:449-451
CrossRef | Web of Science | Medline20
Loewenstein G ,Brennan T ,Volpp KG . Asymmetric paternalism to improve health behaviors. JAMA 2007;298:2415-2417
CrossRef | Web of Science | Medline21
Volpp KG ,Pauly MV ,Loewenstein G ,Bangsberg D . P4P4P: an agenda for research on pay-for-performance for patients. Health Aff (Millwood) 2009;28:206-214
CrossRef | Web of Science | Medline22
Thaler RH . Mental accounting and consumer choice. Marketing Sci 1985;4:199-214
CrossRef23
Annual smoking-attributable mortality, years of potential life lost, and economic costs -- United States, 1995-1999. MMWR Morb Mortal Wkly Rep 2002;51:300-303
Medline24
Pauly MV. Health benefits at work: an economic and political analysis of employment-based health insurance. Ann Arbor: University of Michigan Press, 2002.
25
Barbeau EM ,Li Y ,Sorenson G ,Conlan KM ,Youngstrom R ,Emmons K . Coverage of smoking cessation treatment by union health and welfare funds. Am J Public Health 2001;91:1412-1415
CrossRef | Web of Science | Medline26
Aakko E ,Piasecki TM ,Remington P ,Fiore MC . Smoking cessation services offered by health insurance plans for Wisconsin state employees. WMJ 1999;98:14-18
Medline27
Hughes JR ,Keely J ,Naud S . Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 2004;99:29-38
CrossRef | Web of Science | Medline
- Citing Articles (93)
Citing Articles
1
Karsten Lunze, Michael K. Paasche-Orlow. (2013) Financial Incentives for Healthy Behavior. American Journal of Preventive Medicine 44:6, 659-665
2
MICHAEL R. RICHARDS, JODY L. SINDELAR. (2013) Rewarding Healthy Food Choices in SNAP: Behavioral Economic Applications. Milbank Quarterly 91:2, 395-412
3
Donna M Zulman, Laura J. Damschroder, Ryan G Smith, Paul J. Resnick, Ananda Sen, Erin L Krupka, Caroline R Richardson. (2013) Implementation and evaluation of an incentivized Internet-mediated walking program for obese adults. Translational Behavioral Medicine
4
Alison M. Buttenheim, David A. Asch. (2013) Behavioral Economics: The Key to Closing the Gap on Maternal, Newborn and Child Survival for Millennium Development Goals 4 and 5?. Maternal and Child Health Journal 17:4, 581-585
5
Braden K. Mogler, Suzanne B. Shu, Craig R. Fox, Noah J. Goldstein, Ronald G. Victor, José J. Escarce, Martin F. Shapiro. (2013) Using Insights From Behavioral Economics and Social Psychology to Help Patients Manage Chronic Diseases. Journal of General Internal Medicine 28:5, 711-718
6
Paul SJ Miller, Elyce A Biddle, Johanna Maria van Dongen, Maurits W van Tulder, Emile Tompa, Ian Shemilt, Paul SJ Miller. Economic incentives to enhance safety behaviour in workers for preventing occupational injuries. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2013.
7
Martin S. Hagger, David A. Keatley, Derwin C. K. Chan, Nikos L. D. Chatzisarantis, James A. Dimmock, Ben Jackson, Nikos Ntoumanis. (2013) The Goose Is (Half) Cooked: a Consideration of the Mechanisms and Interpersonal Context Is Needed to Elucidate the Effects of Personal Financial Incentives on Health Behaviour. International Journal of Behavioral Medicine
8
Asch , David A. , Muller , Ralph W. , Volpp , Kevin G. , . (2013) Conflicts and Compromises in Not Hiring Smokers. New England Journal of Medicine 368:15, 1371-1373
Free Full Text9
Thomas Rice. (2013) The Behavioral Economics of Health and Health Care. Annual Review of Public Health 34:1, 431-447
10
(2013) The Art of Health Promotion ideas for improving health outcomes. American Journal of Health Promotion 27:4, TAHP-1-TAHP-12
11
Marita C. Lynagh, Rob W. Sanson-Fisher, Billie Bonevski. (2013) What’s Good for the Goose is Good for the Gander. Guiding Principles for the Use of Financial Incentives in Health Behaviour Change. International Journal of Behavioral Medicine 20:1, 114-120
12
Suchitra Krishnan-Sarin, Dana A. Cavallo, Judith L. Cooney, Ty S. Schepis, Grace Kong, Thomas B. Liss, Amanda K. Liss, Thomas J. McMahon, Charla Nich, Theresa Babuscio, Bruce J. Rounsaville, Kathleen M. Carroll. (2013) An exploratory randomized controlled trial of a novel high-school-based smoking cessation intervention for adolescent smokers using abstinence–contingent incentives and cognitive behavioral therapy. Drug and Alcohol Dependence
13
Meng Li, Gretchen B. Chapman. (2013) Nudge to Health: Harnessing Decision Research to Promote Health Behavior. Social and Personality Psychology Compass 7:3, 187-198
14
Steven Farber, Janet Tate, Cyndi Frank, David Ardito, Michael Kozal, Amy C. Justice, R. Scott Braithwaite. (2013) A Study of Financial Incentives to Reduce Plasma HIV RNA Among Patients in Care. AIDS and Behavior
15
Ciara O’Hagan, Giuseppe Vito, Colin A. G. Boreham. (2013) Exercise Prescription in the Treatment of Type 2 Diabetes Mellitus. Sports Medicine 43:1, 39-49
16
Marco Leyton, Paul Vezina. (2013) Striatal ups and downs: Their roles in vulnerability to addictions in humans. Neuroscience & Biobehavioral Reviews
17
Chelsey R Beane, Suzanne Havala Hobbs, Harsha Thirumurthy. (2013) Exploring the potential for using results-based financing to address non-communicable diseases in low- and middle-income countries. BMC Public Health 13:1, 92
18
José S Marcano Belisario, Michelle N Bruggeling, Laura H Gunn, Serena Brusamento, Josip Car, Josip Car. Interventions for recruiting smokers into cessation programmes. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2012.
19
Saurabh Jha. (2012) Punishing the Lemon: The Ethics of Actuarial Fairness. Journal of the American College of Radiology 9:12, 887-893
20
Marianne Promberger, Paul Dolan, Theresa M. Marteau. (2012) “Pay them if it works”: Discrete choice experiments on the acceptability of financial incentives to change health related behaviour. Social Science & Medicine 75:12, 2509-2514
21
Stefan B. Gingerich, David R. Anderson, Heidi Koland. (2012) Impact of Financial Incentives on Behavior Change Program Participation and Risk Reduction in Worksite Health Promotion. American Journal of Health Promotion 27:2, 119-122
22
Stacey C. Sigmon, Mollie E. Patrick. (2012) The use of financial incentives in promoting smoking cessation. Preventive Medicine 55, S24-S32
23
Meghna Ranganathan, Mylene Lagarde. (2012) Promoting healthy behaviours and improving health outcomes in low and middle income countries: A review of the impact of conditional cash transfer programmes. Preventive Medicine 55, S95-S105
24
Philip. A. Ades, Diann E. Gaalema. (2012) Coronary heart disease as a case study in prevention: Potential role of incentives. Preventive Medicine 55, S75-S79
25
James D. Park, Nandita Mitra, David A. Asch. (2012) Public opinion about financial incentives for smoking cessation. Preventive Medicine 55, S41-S45
26
Harald Schmidt, David A. Asch, Scott D. Halpern. (2012) Fairness and wellness incentives: What is the relevance of the process-outcome distinction?. Preventive Medicine 55, S118-S123
27
Jody L. Sindelar, Nicholas Torsiello. (2012) Optimizing financial incentives to improve health among military personnel: Differences by pay grade and across branches. Preventive Medicine 55, S116-S117
28
Bruce M. Wolfe. (2012) Presidental address—obesity discrimination: what can we do?. Surgery for Obesity and Related Diseases 8:5, 495-500
29
Nancy M. Petry, Carla J. Rash, Shannon Byrne, Shehryar Ashraf, William B. White. (2012) Financial Reinforcers for Improving Medication Adherence: Findings from a Meta-analysis. The American Journal of Medicine 125:9, 888-896
30
B. Bonevski, J. Bryant, M. Lynagh, C. Paul. (2012) Money as motivation to quit: A survey of a non-random Australian sample of socially disadvantaged smokers' views of the acceptability of cash incentives. Preventive Medicine 55:2, 122-126
31
B. Price Kerfoot, Harley Baker. (2012) An Online Spaced-Education Game for Global Continuing Medical Education. Annals of Surgery 256:1, 33-38
32
Anne Kouvonen, Mika Kivimäki, Tuula Oksanen, Jaana Pentti, Tarja Heponiemi, Ari Väänänen, Marianna Virtanen, Jussi Vahtera. (2012) Implementation of Workplace-Based Smoking Cessation Support Activities and Smoking Cessation Among Employees: The Finnish Public Sector Study. American Journal of Public Health 102:7, e56-e62
33
Kristin Voigt. (2012) Incentives, health promotion and equality. Health Economics, Policy and Law 7:03, 263-283
34
Margaret M. Byrne, Jason R. Croft, Michael T. French, Karen L. Dugosh, David S. Festinger. (2012) Development and preliminary results of the Financial Incentive Coercion Assessment questionnaire. Journal of Substance Abuse Treatment 43:1, 86-93
35
H.E. Cuffe, W.T. Harbaugh, J.M. Lindo, G. Musto, G.R. Waddell. (2012) Evidence on the Efficacy of School-Based Incentives for Healthy Living. Economics of Education Review
36
Haiyang Yang, Ziv Carmon, Barbara Kahn, Anup Malani, Janet Schwartz, Kevin Volpp, Brian Wansink. (2012) The Hot–Cold Decision Triangle: A framework for healthier choices. Marketing Letters 23:2, 457-472
37
Raphael J. Landovitz, Jesse B. Fletcher, Galina Inzhakova, Jordan E. Lake, Steven Shoptaw, Cathy J. Reback. (2012) A Novel Combination HIV Prevention Strategy: Post-Exposure Prophylaxis with Contingency Management for Substance Abuse Treatment Among Methamphetamine-Using Men Who Have Sex with Men. AIDS Patient Care and STDs 26:6, 320-328
38
Marewa Glover, Trish Fraser, Vili Nosa. (2012) Views of Low Socio-Economic Smokers: What Will Help Them to Quit?. Journal of Smoking Cessation 7:01, 41-46
39
Annice E. Kim, Angela Towers, Jeanette Renaud, Jingsan Zhu, Judy A. Shea, Robert Galvin, Kevin G. Volpp. (2012) Application of the RE-AIM Framework to Evaluate the Impact of a Worksite-Based Financial Incentive Intervention for Smoking Cessation. Journal of Occupational and Environmental Medicine 54:5, 610-614
40
Stephen T. Higgins, Kenneth Silverman, Stacey C. Sigmon, Neal A. Naito. (2012) Incentives and health: An introduction. Preventive Medicine
41
William H. Shrank, Niteesh K. Choudhry. (2012) Therapy: Affect and affirmations—a 'basic' approach to promote adherence. Nature Reviews Cardiology 9:5, 263-265
42
Matthew H. Levine, Peter P. Reese, Alexander Wood, Jorge H. Baluarte, Ari Huverserian, Ali Naji, Peter L. Abt. (2012) Inferior Allograft Outcomes in Adolescent Recipients of Renal Transplants From Ideal Deceased Donors. Annals of Surgery 255:3, 556-564
43
B. Price Kerfoot, Harley Baker. (2012) An Online Spaced-Education Game to Teach and Assess Residents: A Multi-Institutional Prospective Trial. Journal of the American College of Surgeons 214:3, 367-373
44
Andrea B. Troxel, Kevin G. Volpp. (2012) Effectiveness of Financial Incentives for Longer-Term Smoking Cessation: Evidence of Absence or Absence of Evidence?. American Journal of Health Promotion 26:4, 204-207
45
Rebecca L. Ashare, Larry W. Hawk. (2012) Effects of smoking abstinence on impulsive behavior among smokers high and low in ADHD-like symptoms. Psychopharmacology 219:2, 537-547
46
Paul M Ridker, Peter Libby. Risk Markers for Atherothrombotic Disease. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. Elsevier, 2012:914-934.
47
Jean-François Etter. (2012) Financial incentives for smoking cessation in low-income smokers: study protocol for a randomized controlled trial. Trials 13:1, 88
48
Harald Schmidt. (2012) Anreize für Eigenverantwortung: Begriffsbestimmung und Evidenzlage. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 106:3, 185-194
49
David M Tappin, Linda Bauld, Carol Tannahill, Linda de Caestecker, Andrew Radley, Alex McConnachie, Kathleen Boyd, Andrew Briggs, Liz Grant, Alan Cameron, Susan MacAskill, Lesley Sinclair, Brenda Friel, Tim Coleman. (2012) The Cessation in Pregnancy Incentives Trial (CPIT): study protocol for a randomized controlled trial. Trials 13:1, 113
50
Harald Schmidt. (2012) Wellness Incentives, Equity, and the 5 Groups Problem. American Journal of Public Health 102:1, 49-54
51
Jeroen Vanderhoeven, Jorge E. Tolosa. Smoking. Informa Healthcare, 2011:153-160.
52
Jamie Bryant, Billie Bonevski, Chris Paul, Patrick McElduff, John Attia. (2011) A systematic review and meta-analysis of the effectiveness of behavioural smoking cessation interventions in selected disadvantaged groups. Addiction 106:9, 1568-1585
53
Hayden B. Bosworth, Bradi B. Granger, Phil Mendys, Ralph Brindis, Rebecca Burkholder, Susan M. Czajkowski, Jodi G. Daniel, Inger Ekman, Michael Ho, Mimi Johnson, Stephen E. Kimmel, Larry Z. Liu, John Musaus, William H. Shrank, Elizabeth Whalley Buono, Karen Weiss, Christopher B. Granger. (2011) Medication adherence: A call for action. American Heart Journal 162:3, 412-424
54
Paul E. Terry, David R. Anderson. (2011) Finding Common Ground in the Use of Financial Incentives for Employee Health Management: A Call for a Progress-Based Approach. American Journal of Health Promotion 26:1, ev-evii
55
Peter Anderson, Oliver Harrison, Cary Cooper, Eva Jané-Llopis. (2011) Incentives for Health. Journal of Health Communication 16:sup2, 107-133
56
Volpp , Kevin G. , Asch , David A. , Galvin , Robert , Loewenstein , George , . (2011) Redesigning Employee Health Incentives — Lessons from Behavioral Economics. New England Journal of Medicine 365:5, 388-390
Free Full Text57
Hannah Parke, Richard Ashcroft, Rebecca Brown, Theresa M Marteau, Clive Seale. (2011) Financial incentives to encourage healthy behaviour: an analysis of UK media coverage. Health Expectationsno-no
58
Rei Goto, Yuko Takahashi, Takanori Ida. (2011) Changes in Smokers' Attitudes Toward Intended Cessation Attempts in Japan. Value in Health 14:5, 785-791
59
BILLIE BONEVSKI, JAMIE BRYANT, CHRISTINE PAUL. (2011) Encouraging smoking cessation among disadvantaged groups: A qualitative study of the financial aspects of cessation. Drug and Alcohol Review 30:4, 411-418
60
Priya Shetty. (2011) Cash cure for the AIDS epidemic?. Nature
61
Jill S Rumberger, Christopher S Hollenbeak. (2011) Potential Costs and Benefits of Statewide Smoking Cessation in Pennsylvania. The Journal of Smoking Cessation 6:1, 25-32
62
Gregory M. Lucas. (2011) Substance abuse, adherence with antiretroviral therapy, and clinical outcomes among HIV-infected individuals. Life Sciences 88:21-22, 948-952
63
Paul Aveyard, Linda Bauld, David Tovey. Incentives for promoting smoking cessation: What we still do not know. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2011.
64
Kate Cahill, Rafael Perera, Kate Cahill. Competitions and incentives for smoking cessation. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2011.
65
Mukul Sharma, Antoine M. Hakim. (2011) The management of hypertension for primary stroke prevention: a proposed approach. International Journal of Stroke 6:2, 144-149
66
Thomas M. Maddox, P. Michael Ho. The Role of Treatment Adherence in Cardiac Risk Factor Modification. In: Preventive Cardiology: Companion to Braunwald's Heart Disease. Elsevier, 2011:570-578.
67
Alan D. Smith, Amber A. Smith. (2011) Gender perceptions of smoking and cessation via technology, incentives and virtual communities. International Journal of Electronic Healthcare 6:1, 1
68
Chang Dong Yeo, Hyeon Hui Kang, Ji Young Kang, Sung Kyoung Kim, Myung Sook Kim, Seung Soo Kim, Sang Haak Lee, Hwa Sik Moon. (2011) A Short-Term Effectiveness of Smoking Cessation Intervention in Outpatient Department of Pulmonology. Tuberculosis and Respiratory Diseases 71:2, 114
69
John Cawley, Christopher J. Ruhm. The Economics of Risky Health Behaviors. Elsevier, 2011:95-199.
70
Annice Kim, Kian Kamyab, Jingsan Zhu, Kevin Volpp. (2011) Why are Financial Incentives not Effective at Influencing Some Smokers to Quit? Results of a Process Evaluation of a Worksite Trial Assessing the Efficacy of Financial Incentives for Smoking Cessation. Journal of Occupational and Environmental Medicine 53:1, 62-67
71
Jill S Rumberger, Christopher S Hollenbeak. (2010) Potential Costs and Benefits of Statewide Smoking Cessation in Pennsylvania. The Journal of Smoking Cessation 5:2, 136-144
72
Hayden B. Bosworth, Benjamin J. Powers, Eugene Z. Oddone. (2010) Patient Self-Management Support: Novel Strategies in Hypertension and Heart Disease. Cardiology Clinics 28:4, 655-663
73
Stephen T. Higgins. (2010) Comments on contingency management and conditional cash transfers. Health Economics 19:10, 1255-1258
74
Xavier Giné, Dean Karlan, Jonathan Zinman. (2010) Put Your Money Where Your Butt Is: A Commitment Contract for Smoking Cessation. American Economic Journal: Applied Economics 2:4, 213-235
75
Matthew R. Gingo, M. Patricia George, Cathy J. Kessinger, Lorrie Lucht, Barbara Rissler, Renee Weinman, William A. Slivka, Deborah K. McMahon, Sally E. Wenzel, Frank C. Sciurba, Alison Morris. (2010) Pulmonary Function Abnormalities in HIV-Infected Patients during the Current Antiretroviral Therapy Era. American Journal of Respiratory and Critical Care Medicine 182:6, 790-796
76
Eran Klein, Jason Karlawish. (2010) Challenges and Opportunities for Developing and Implementing Incentives to Improve Health-Related Behaviors in Older Adults. Journal of the American Geriatrics Society 58:9, 1758-1763
77
J. Hsia. (2010) Managing cardiovascular risk factors: Trial evidence in women. Nutrition, Metabolism and Cardiovascular Diseases 20:6, 445-450
78
Darla E. Kendzor, Michael S. Businelle, Tracy J. Costello, Yessenia Castro, Lorraine R. Reitzel, Ludmila M. Cofta-Woerpel, Yisheng Li, Carlos A. Mazas, Jennifer Irvin Vidrine, Paul M. Cinciripini, Anthony J. Greisinger, David W. Wetter. (2010) Financial Strain and Smoking Cessation Among Racially/Ethnically Diverse Smokers. American Journal of Public Health 100:4, 702-706
79
Kimberly D. Leeks, David P. Hopkins, Robin E. Soler, Adam Aten, Sajal K. Chattopadhyay. (2010) Worksite-Based Incentives and Competitions to Reduce Tobacco Use. American Journal of Preventive Medicine 38:2, S263-S274
80
L.T. Tanoue. (2010) A Randomized, Controlled Trial of Financial Incentives for Smoking Cessation. Yearbook of Pulmonary Disease 2010, 122-124
81
Charles M. Preston, Miriam Alexander. (2010) Prevention in the United States Affordable Care Act. Journal of Preventive Medicine and Public Health 43:6, 455
82
Yoo Seock Cheong, Sang Hyun Ahn. (2010) Effect of Multi-modal Interventions for Smoking Cessation in a University Setting: A Short Course of Varenicline, Financial Incentives, E-mail and Short Message Service. Korean Journal of Family Medicine 31:5, 355
83
Yong Hyun Kim, Sang Haak Lee. (2010) Smoking Cessation. Tuberculosis and Respiratory Diseases 69:3, 153
84
Wasim Maziak, Kenneth D. Ward. (2009) From Health as a Rational Choice to Health as an Affordable Choice. American Journal of Public Health 99:12, 2134-2139
85
Evan S. Fieldston, Andrea Puig, Judy A. Shea, Joshua P. Metlay, Susmita Pati. (2009) Physicians’ Views on Incentives for Adherence in Childhood Asthma. Pediatric Asthma, Allergy & Immunology 22:4, 175-188
86
Mark A. Hlatky, Paul Heidenreich. (2009) The Year in Epidemiology, Health Services Research, and Outcomes Research. Journal of the American College of Cardiology 54:25, 2343-2351
87
M. F. Hovell, S. C. Hughes. (2009) The behavioral ecology of secondhand smoke exposure: A pathway to complete tobacco control. Nicotine & Tobacco Research 11:11, 1254-1264
88
(2009) The Art of Health Promotion. American Journal of Health Promotion 24:1, TAHP-1-TAHP-12
89
Volpp , Kevin G. , Das , Anup . (2009) Comparative Effectiveness — Thinking beyond Medication A versus Medication B. New England Journal of Medicine 361:4, 331-333
Free Full Text90
(2009) Être payé pour arrêter de fumer, ça marche… mieux. Revue Francophone des Laboratoires 2009:411, 20
91
T.L. Bauer. (2009) A Randomized, Controlled Trial of Financial Incentives for Smoking Cessation. Yearbook of Medicine 2009, 165-166
92
T.L. Bauer. (2009) A Randomized, Controlled Trial of Financial Incentives for Smoking Cessation. Yearbook of Oncology 2009, 129-130
93
Iñaki Lekuona Goya, Alberto Salcedo Arruti, Miren Morillas Bueno, Juana Umaran Sánchez. (2009) Tabaco y enfermedad arterial no coronaria. Intervenciones para el abandono del hábito tabáquico. Revista Española de Cardiología Suplementos 9:4, 39-48
